Performance of Different Imaging Modalities in the Localization of Insulinomas (Benign Insulinomas)
| Modality | Imaging modality | Sensitivity | Reference* |
|---|---|---|---|
| Nuclear medicine | GLP-1R PET/CT | 85%–98% | (22,24,32) |
| GLP-1R SPECT/CT | 69% | (22) | |
| SSTR PET/CT | 55%–87% | (32,47) | |
| SSTR SPECT/CT | 20%–29% | (24,27) | |
| 18F-DOPA PET/CT | 50%–73% | (34,35) | |
| Radiology | ceMRI | 56%–90% | (22,23,24,25,26) |
| Multiphase ceCT | 47%–74% | (23,24,25,26, 27,35) | |
| Invasive imaging | EUS | 70%–100% | (23,24,25,27, 35,48,49,50) |
| ASVS | 65%–100% | (27,48,49,51,52) |
↵* References include all English written literature not older than 6 y with more than 12 patients per study using the following keywords: localization of insulinoma or endogenous hyperinsulinemic hypoglycemia. Only exception are 18F-DOPA PET/CT studies, as trials with more than 12 patients were not available.
EUS = endoscopic ultrasound; ASVS = selective intraarterial calcium stimulation and venous sampling.